US Pharma MarketingASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma - Pharmaceutical Technology
Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ESOT-01. Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ESOT-01. In vivo CAR-T therapies like KLN-1010 and ESOT-01 remain in early development. Credit: Krot-Studio/Shutterstock.com Kelonia Therapeutics presented results for the Phase I inMMyCAR clinical trial (NCT07075185) at the American Society of Clinical Oncology (ASCO) 2026 meeting, held May 29–June 2, 2026. The trial features an in vivo chimeric antigen receptor (CAR)-T cell therapy, KLN-1010, administered in patients with relapsed or refractory (r/r)…
Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ESOT-01.
Source: Pharmaceutical Technology